Format

Send to

Choose Destination
Malar J. 2012 Aug 22;11:292. doi: 10.1186/1475-2875-11-292.

A framework for assessing the risk of resistance for anti-malarials in development.

Author information

1
Medicines for Malaria Venture, 20 rte de Pré Bois, Geneva CH 1215, Switzerland. dingx@mmv.org

Abstract

Resistance is a constant challenge for anti-infective drug development. Since they kill sensitive organisms, anti-infective agents are bound to exert an evolutionary pressure toward the emergence and spread of resistance mechanisms, if such resistance can arise by stochastic mutation events. New classes of medicines under development must be designed or selected to stay ahead in this vicious circle of resistance control. This involves both circumventing existing resistance mechanisms and selecting molecules which are resilient against the development and spread of resistance. Cell-based screening methods have led to a renaissance of new classes of anti-malarial medicines, offering us the potential to select and modify molecules based on their resistance potential. To that end, a standardized in vitro methodology to assess quantitatively these characteristics in Plasmodium falciparum during the early phases of the drug development process has been developed and is presented here. It allows the identification of anti-malarial compounds with overt resistance risks and the prioritization of the most robust ones. The integration of this strategy in later stages of development, registration, and deployment is also discussed.

PMID:
22913649
PMCID:
PMC3478971
DOI:
10.1186/1475-2875-11-292
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center